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Abstract.
Background: Previous cross-sectional studies have shown that Parkinson’s disease (PD) patients have lower serum 25-
hydroxy vitamin D (25(OH)D) concentrations than controls. Vitamin D deficiency was associated with increased disease
severity and cognitive impairment in prevalent PD patients.
Objective: The aim of the study was to determine 25(OH)D in newly diagnosed PD and age-matched controls and to assess
if there was an association with clinical outcomes (disease severity, cognition and falls) over the 36-month follow up period.
Methods: A prospective observational study of newly diagnosed PD patients in the North East of England with age-matched
controls (PD, n = 145; control, n = 94). Serum 25(OH)D was assessed at baseline and 18 months. Participants underwent
clinical assessment at baseline, 18 and 36 months. One hundred and ten participants with PD also took part in a prospective
falls study.
Results: Mean serum 25(OH)D concentrations were lower in PD than control participants at baseline (44.1 ± 21.7 vs.
52.2 ± 22.1 nmol/L, p < 0.05) and 18 months (44.2 ± 23.6 vs. 55.7 ± 28.8 nmol/L, p < 0.05). Baseline serum 25(OH)D
concentration, age, motor score and dosage of dopaminergic medication were significant predictors of variance of motor
severity at 36 months ((R2 = 0.039, F = 6.6, p < 0.01). Serum 25(OH)D was not associated with cognition or falls during
the follow up period.
Conclusion: Patients with incident PD had significantly lower serum 25(OH)D concentrations than age-matched controls,
which may have implications in terms of bone health and fracture risk. There was a small but significant association between
vitamin D status at baseline and disease motor severity at 36 months.
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INTRODUCTION
Idiopathic Parkinson’s disease (PD) is the sec-
ond most common neurodegenerative disorder in the
United Kingdom (UK) after Alzheimer’s disease,
with increasing age being the greatest risk factor for
the development of the disorder. Thus, any interven-
tions with the potential to reduce the incidence of
the disease or its complications receive considerable
attention.
Outdoor work has been associated with a reduced
risk of developing PD in later life. Danish men who
worked outdoors were less likely to develop PD than
men who worked indoors (odds ratio 0.72 (95% CI
0.63 to 0.82)) [1]. One possible mechanism for the
protective effect of outdoor work may be increased
exposure to sunlight, which leads to cutaneous vita-
min D synthesis. This hypothesis is supported by a
Finnish study, which showed that middle-aged peo-
ple with a serum 25-hydroxy vitamin D (25(OH)D)
concentration in the highest quartile were a third less
likely to develop PD than those in the bottom quartile
[2]. A recent study in France used population data to
show that areas with higher UV-B radiation had lower
rates of prescription of dopaminergic medications
in the under 70 s, suggesting lower rates of PD [3].
This is the first data looking at the link between sun-
light exposure and risk of PD, however, the estimated
sunlight exposure may vary significantly between
individuals. Conversely, a recent study in the United
States has failed to confirm the association between
mid-life vitamin D status and prospective risk of PD
[4]. This may be related to the higher population vita-
min D levels in the US compared to Finland. These
findings suggest that an increased risk may be partic-
ularly found amongst those with a very low vitamin
D status, also common in the UK. Therefore, further
studies in well-designed cohorts are required.
As postmortem studies have shown that there are
vitamin D receptors on dopaminergic neurons in the
human substantia nigra, it has been suggested that
vitamin D may be able to protect dopaminergic neu-
rons [5]. Whilst this has not been directly proven in
humans, the administration of vitamin D in animal
models of PD were found to be neuroprotective to
dopaminergic neurons [6].
Cross-sectional studies have demonstrated that
patients with established PD have significantly lower
plasma concentrations of 25(OH)D than age-matched
controls [7, 8]. Vitamin D deficiency has been corre-
lated with increasing motor severity, postural insta-
bility [9] as well as poorer verbal fluency and memory
[10]. It is unclear if these effects are specific to PD, as
vitamin D deficiency is also associated with postural
instability [11] and cognitive impairment [12] in com-
munity dwelling older adults. While these studies of
the general older population have been large and well
designed, the studies of PD participants have small
numbers and cross-sectional design, making it diffi-
cult to determine if vitamin D status is an independent
risk factor, or a marker of disease severity.
We therefore sought to determine vitamin D status
in a longitudinal cohort of incident PD subjects and
age-matched controls at time of PD diagnosis and 18
months later. Secondary outcome measures included
associations between vitamin D status and cognition,
motor severity and time to first fall among participants
with PD over 36 months follow-up.
METHODS
Participants
Patients with newly diagnosed PD in Newcastle
upon Tyne and Gateshead, England (latitude 55◦
North) were recruited to the Incidence of Cog-
nitive Impairment in Cohorts with Longitudinal
Evaluation - Parkinson’s disease (ICICLE-PD) study
between June 2009 and December 2011, as previ-
ously described [13, 14]. PD participants fulfilled
the UK Brain Bank Criteria for idiopathic PD [15].
Exclusion criteria were: significant memory impair-
ment at baseline (defined by Mini-Mental State Score
(MMSE)<24 or fulfilling the Movement Disorder
Society PD dementia (PDD) criteria [16]; Lewy body
dementia; insufficient English to complete neuropsy-
chological assessments; or a diagnosis of atypical,
vascular or drug-induced Parkinsonism.
Healthy control subjects were recruited locally by
advertising, word of mouth and community groups.
Spouses, relatives and carers were not eligible to
limit bias. Control subjects were excluded if they had
a major psychiatric disorder, cognitive impairment,
previous stroke, or movement disorder.
All of the control participants were Caucasian
(n = 94). One of the PD participants (n = 145)
was African; three were Asian and the remainder
Caucasian.
Ethics
The study was approved by Newcastle and North
Tyneside Research Ethics Committee. All partici-
pants provided written informed consent.
I. Sleeman et al. / Vitamin D in Early Parkinson’s Disease 671
Clinical assessment
All subjects underwent a clinical assessment
at baseline, 18 and 36 months. Each assessment
included a clinical history including comorbidities,
current medication use and social history, and a clin-
ical examination by a movement disorder specialist.
The PD group also underwent assessment of their dis-
ease using the Movement Disorder Society Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS)
parts II and III [17], and Hoehn and Yahr scale
[18]. Mood was assessed using the 15-point Geri-
atric Depression Scale [19]. Cognition was assessed
using the MMSE [20], and two batteries of comput-
erised tests – the Cognitive Drug Research (CDR)
battery [21] and Cambridge Neuropsychological Test
Automated Battery (CANTAB) [22], as described
previously [14]. A diagnosis of mild cognitive impair-
ment in PD (PD-MCI) was based on a modified
version of the criteria defined by the Movement
Disorder Society taskforce, in common with other
ICICLE publications, using two standard deviations
as the cut off [23]. Motor and cognitive testing was
performed with participants having taken their usual
medication.
A subset of consenting participants (n = 110) with
PD completed monthly prospective falls diaries for
36 months as part of a nested study (ICICLE-GAIT).
A fall was defined as an event that causes a person to
unintentionally come to rest on the ground or another
lower level [24]. Participants were asked to record if
they had fallen in the previous month and to give the
date, time, location and circumstances of any falls.
Study staff called participants to verify the details of
any reported falls and to seek clarification if required.
Falls study participants did not differ from the whole
group with respect to age, gender, disease duration
and severity at baseline (data not shown).
Vitamin D analysis
Serum 25(OH)D levels were determined at base-
line and 18 months. Blood samples were drawn
while fasting. Samples were centrifuged (4000 rota-
tions per minute for 10 minutes at 19◦C), and
serum was transferred into cryovials and stored at
–80◦C. Samples were transferred to the MRC Human
Nutrition Research (HNR) in Cambridge on dry ice
for analysis. They were analysed individually by
liquid chromatography tandem mass spectrometry
(LC-MSMS) to determine 25(OH)D2 and 25(OH)D3
concentration. Total 25(OH)D concentration was
determined by summing 25(OH)D2 and 25(OH)D3
concentration. The HNR laboratory is a mem-
ber of the Vitamin D Standardisation Programme
(VDSP), and quality assurance of 25(OH)D assays
are performed as part of the Vitamin D Exter-
nal Quality Assessment Scheme (www.deqas.org).
Assay performance was monitored using Chromsys-
tems and in-house controls. The inter assay variation
was <10% for 25(OH)D2 and <7% for 25(OH)D3 and
the limit of quantification was 6nmol/L.
Statistical analysis
Data were analysed using IBM SPSS 22. They
were checked for normality by visual inspection
of histograms and the Kolmogorov-Smirnov test
and compared using independent t-tests or Mann-
Whitney U tests, depending on distribution. The
chi-square test was used to assess binary outcome
variables. The significance level for all statistical tests
was set at 0.05 two-tailed.
As serum samples were drawn throughout the year,
serum 25(OH)D concentration varied by season in
both the PD patients and controls, which made com-
parison between individuals unfeasible. Control data
for baseline and 18 months was therefore pooled
and a standard curve derived (See Supplementary
Figure 1). Data for individuals was then compared to
the mean, difference from the mean was calculated to
give an adjusted serum 25(OH)D value at baseline.
This value was then used in the models described
below. Effect size was determined using eta-squared
coefficients.
Multiple regression was performed to determine
significant predictors of disease severity using MDS-
UPDRS part III score at 36 months. Preliminary
analyses were conducted to ensure no violations
of the assumptions of normality, linearity, mul-
ticollinearity and homoscedasticity. Predictors of
MDS-UPDRS part III score at 36 months com-
prised baseline age, MDS-UPDRS part III score and
levodopa equivalent dose (LED). Serum 25(OH)D
concentration, adjusted as described above, was then
added to the model.
Logistic regression was used to predict cognition at
36 months using PD-MCI classification as the depen-
dent variable. Based on previous work, covariates
entered into the models included baseline age and
years of education as predictors of cognition [14].
Falls data was dichotomised to compare partici-
pants who were above and below the threshold for
vitamin D deficiency (50 nmol/L 25(OH)D). Time
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to first fall was plotted as a Kaplan-Meier curve and
survival between groups compared using the log rank
test. Cox regression was used to determine if vitamin
D deficiency was associated with shorter time to first
fall, after adjusting for risk factors, such as previous
falls, disease severity, and MMSE score [25].
RESULTS
Baseline characteristics
At baseline, 145 PD and 94 control partici-
pants were included (see Flowchart; Supplementary
Figure 2). Participant baseline characteristics are
shown in Table 1. PD and control groups were well
matched for age. As previously described [14], sub-
jects with PD demonstrated impairments on measures
of cognition and mood compared to the control group.
Vitamin D at baseline
Mean serum 25(OH)D concentrations were sig-
nificantly lower at baseline in PD participants than
controls (44.1 ± 21.7 (mean ± SD) vs. 52.2 ± 22.1
nmol/L, respectively, p = 0.005, Fig. 1). Effect size
was moderate (eta-squared = 0.067). Fifty-eight con-
trols (61.7%) and 60 PD participants (41.4%) had the
serum sample drawn in winter or spring (December to
May), meaning that significantly more controls had
*
Fig. 1. Serum 25(OH)D concentration at baseline (PD, n = 145,
control n = 94. Data represent median ± 95% confidence interval.
*p = 0.02 versus control participants (Mann Whitney U test).
a sample drawn when serum vitamin D was likely
to be at its lowest (χ2 = 8.05, p = 0.03). There was
no significant difference in serum vitamin D between
those who did and did not take vitamin D supplements
(p > 0.05 for both groups).
Vitamin D at 18 months
At 18 months, mean serum 25(OH)D concentra-
tions were again significantly lower among PD par-
ticipants than controls (44.2 ± 23.6 vs. 55.7 ± 28.8
Table 1
Characteristics of participants at baseline (data are mean (SD) unless stated)
Control participants PD participants P value
N = 94 N = 145
Age (years) 68.2 (8.1) 66.2 (11.7) 0.41a
Male, n (%) 50 (53.2) 94 (64.8) 0.09b
Height (m) 1.7 (0.1) 1.7 (0.2) 0.53c
Weight (kg) 80.2 (14.2) 79.0 (16.3) 0.55c
Disease duration (months) n/a 6.2 (6.1) n/a
LEDD (mg/day) n/a 168.8 (129.8) n/a
Hoehn and Yahr stage n/a 2.0 (0.7) n/a
MDS-UPDRS Part II n/a 10.9 (5.8) n/a
MDS-UPDRS Part III n/a 26.6 (11.9) n/a
MMSE score 29.0 (1.2) 28.6 (1.4) <0.01c
PD-MCI 2 SD, n (%) 9 (9.6) 37 (25.5) 0.002b
GDS-15 1.0 (1.6) 2.8 (2.6) <0.001a
Education, years 13.1 (3.4) 12.8 (3.9) 0.29c
Serum 25(OH)D (nmol/L) 52.2 (22.1) 44.1 (21.7) <0.005c
% vitamin D insufficient 25(OH)D<75 nmol/L 79.8% 91.0% 0.02b
Serum 25(OH)D deficiency (<50 nmol/L) 45.7% 66.9% <0.01b
Number on vitamin D supplements, n (%) 6 (6.4%) 11 (7.6%) 1.0b
GDS-15: Geriatric Depression Scale score; IQR: interquartile range; LEDD; levodopa-equivalent daily dose; PD-MCI 2
SD: mild cognitive impairment with the cut-off 2 standard deviations from normal; MMSE: Mini Mental State Examination;
MDS-UPDRS: Movement Disorders Society Unified Parkinson’s Disease Rating Scale. aMann-Whitney U test, bFisher’s
exact test, cindependent t-test.
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nmol/L, respectively, p = 0.002). Controls were
significantly more likely to have their serum sam-
ple drawn in summer or autumn (June to November).
Twenty-five control subjects (32.1%) and 66 PD
subjects (54.5%) had the serum sample drawn in
winter or spring (χ2 = 8.54, p = 0.03). Eight control
and 15 PD participants took vitamin D supplements
at 18 months (Fisher’s exact test, p > 0.05 for both
groups).
Cognition
At 36 months, data on cognition was available
for 105 PD patients and 70 controls. Participants
with PD were signficantly more likely to have MCI
than controls (50.5% vs. 9.7%, χ2 = 29.36, p < 0.001).
Logistic regression revealed that baseline age, GDS
score, years of education and disease group produced
a reasonable model of MCI at 36 months (χ2 = 74.96,
p < 0.001), which was not improved by the addition
of baseline adjusted vitamin D status (Supplementary
Table 1).
Motor progression
We examined the relationship between vitamin D
status and severity of motor impairment in partici-
pants with PD over 36 months. Mean MDS-UPDRS
III score increased from 27.0 ± 12.0 at baseline
to 38.6 ± 13.2 at 36 months. Multiple regression
revealed that baseline age, MDS-UPDRS III score
and LED were significant predictors of variance of
motor severity at 36 months (adjusted R2 = 0.368,
F = 19.6, p < 0.001), which was improved when base-
line 25(OH)D was added to the model (R2 = 0.039,
F = 6.6, p < 0.01; Supplementary Table 2).
Falls
The median time of first fall amongst 110 PD
participants who completed prospective falls diaries
from baseline was 15.9 months (IQR = 1.1–30.8).
There was no difference in the time to first fall
between participants who were vitamin D deficient
(25(OH)D<50 nmol/L) or replete (Fig. 2, log rank
test, p = 0.32). Furthermore, Cox regression adjust-
ing for previous falls, baseline MDS-UPDRS III and
MMSE score did not reveal an increased hazard of
falling among those who were vitamin D deficient
(p = 0.30).
Fig. 2. Time in months to first fall in falls diary PD participants
who had above (n = 55) or below (n = 55) the median vitamin D.
There was no significant difference in time-to-first-fall between
the groups (log rank test, p = 0.23).
DISCUSSION
We have shown that participants with early PD
have lower serum concentrations of 25(OH)D than
control participants within months of diagnosis, and
at 18 months follow-up. Low baseline 25(OH)D
concentration was associated with a higher MDS-
UPDRS III score and thus greater motor severity at
36 months. No association was found between vita-
min D status at baseline and time to first fall or risk
of PD-MCI.
The results for the control participants are con-
sistent with a previous study in the UK, which
demonstrated that community dwelling men and
women over 65 had median serum 25(OH)D concen-
trations of 50.5 and 43.0 nmol/L respectively [26].
In common with previous cross-sectional and longi-
tudinal [8] studies, we found that serum 25(OH)D
concentrations were significantly lower in partici-
pants with PD than controls. In our study, however,
serum 25(OH)D was tested closer to the start of the
disease (typically less than six months) than previ-
ously, which lends support to the hypothesis that
vitamin D may have a role in disease progression.
In terms of the 25(OH)D concentrations, our results
were comparable to another Northern European study
of patients with established disease (median duration
4.5 years) where again participants with PD had sig-
nificantly lower vitamin D levels than controls (48.3
vs 56.9 nmol/L) [29].
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Studies in North America have revealed much
higher 25(OH)D concentrations in PD than seen in
this work performed in Newcastle upon Tyne, UK
(latitude 55◦ North). The DATATOP study, based
in Atlanta, Georgia, USA (34◦ North), found that
69.4% of participants were vitamin D insufficient
(defined as less than 75 nmol/L) at 18 months [8],
compared to 91.0% in our study. Similarly, in the Har-
vard Biomarkers Study, based in Boston, MA, USA
(42◦ North) mean 25(OH)D concentration was 70.0
nmol/L in a cohort of patients with a median disease
duration of 4.9 years [6].
Two studies in Portland, Oregon, USA (45◦ North)
showed associations between serum 25(OH)D and
balance [9], and the risk of PD dementia [10]. Both
studies reported much higher serum 25(OH)D con-
centrations than our study (median ∼85 nmol/L),
which is likely to be related to latitude, although the
wider use of supplements and food fortification in the
US may have contributed. Dietary intake of vitamin D
in the US is higher than in the UK (on average 7.3 ver-
sus 3.7 microgram/day [27]). It is therefore possible
that the lack of association between serum 25(OH)D
and functional outcomes in our study may be due to
a ‘floor effect’, whereby there are no differences in
function at such low 25(OH)D concentrations.
The main strengths of the study are longitudinal
design, inclusion of a control group and use of the
most reliable method of determining serum 25(OH)D
concentration (tandem mass spectrometry) [28]. Lim-
itations include the fact that 25(OH)D concentrations
vary significantly during the year, peaking in late
summer [26]. However, in this study serum samples
were drawn throughout the year as participants were
recruited and re-assessed at 18 months. This meant
that 25(OH)D concentrations were not directly com-
parable between participants and may have blunted
our ability to find associations between vitamin D
status and clinical parameters. A small number of par-
ticipants took vitamin D or multivitamin supplements
during the study which may have influenced the
results. However, no significant differences between
those who did and did not take supplements were not
found. In addition, we repeated the regression anal-
ysis excluding these participants and the models did
not significantly differ (data not shown).
The main clinical significance of this work relates
both to the small but significant association between
baseline 25(OH)D concentration and motor severity,
as assessed using MDS-UPDRS III at 36 months.
In addition, this work has relevance to bone health
in Parkinson’s disease. Previous research has shown
a high prevalence of osteopenia and osteoporosis in
cross-sectional cohorts of Parkinson’s patients, plac-
ing patients at greater risk of bone fractures should
they fall. More recently, work from an incidence
cohort of Parkinsonian patients and age matched
controls has revealed that an increased risk of
major bone fracture following a fall from diagnosis
onwards (4.2% vs 1.4% per year) [29]. As vita-
min D deficiency is a well-established risk factor
for osteoporosis [30], our finding that the majority
of newly diagnosed patients with PD are vitamin D
deficient suggests that clinicians should be routinely
assessing fracture risk at diagnosis and treating as
appropriate [31].
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